Literature DB >> 10751429

UB-165: a novel nicotinic agonist with subtype selectivity implicates the alpha4beta2* subtype in the modulation of dopamine release from rat striatal synaptosomes.

C G Sharples1, S Kaiser, L Soliakov, M J Marks, A C Collins, M Washburn, E Wright, J A Spencer, T Gallagher, P Whiteaker, S Wonnacott.   

Abstract

Presynaptic nicotinic acetylcholine receptors (nAChRs) on striatal synaptosomes stimulate dopamine release. Partial inhibition by the alpha3beta2-selective alpha-conotoxin-MII indicates heterogeneity of presynaptic nAChRs on dopamine terminals. We have used this alpha-conotoxin and UB-165, a novel hybrid of epibatidine and anatoxin-a, to address the hypothesis that the alpha-conotoxin-MII-insensitive subtype is composed of alpha4 and beta2 subunits. UB-165 shows intermediate potency, compared with the parent molecules, at alpha4beta2* and alpha3-containing binding sites, and resembles epibatidine in its high discrimination of these sites over alpha7-type and muscle binding sites. (+/-)-Epibatidine, (+/-)-anatoxin-a, and (+/-)-UB-165 stimulated [(3)H]-dopamine release from striatal synaptosomes with EC(50) values of 2.4, 134, and 88 nM, and relative efficacies of 1:0.4:0.2, respectively. alpha-Conotoxin-MII inhibited release evoked by these agonists by 48, 56, and 88%, respectively, suggesting that (+/-)-UB-165 is a very poor agonist at the alpha-conotoxin-MII-insensitive nAChR subtype. In assays of (86)Rb(+) efflux from thalamic synaptosomes, a model of an alpha4beta2* nAChR response, (+/-)-UB-165 was a very weak partial agonist; the low efficacy of (+/-)-UB-165 at alpha4beta2 nAChR was confirmed in Xenopus oocytes expressing various combinations of human nAChR subunits. In contrast, (+/-)-UB-165 and (+/-)-anatoxin-a were similarly efficacious and similarly sensitive to alpha-conotoxin-MII in increasing intracellular Ca(2+) in SH-SY5Y cells, a functional assay for native alpha3-containing nAChR. These data support the involvement of alpha4beta2* nAChR in the presynaptic modulation of striatal dopamine release and illustrate the utility of exploiting a novel partial agonist, together with a selective antagonist, to dissect the functional roles of nAChR subtypes in the brain.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10751429      PMCID: PMC6772190     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  44 in total

1.  Upregulation of surface alpha4beta2 nicotinic receptors is initiated by receptor desensitization after chronic exposure to nicotine.

Authors:  C P Fenster; T L Whitworth; E B Sheffield; M W Quick; R A Lester
Journal:  J Neurosci       Date:  1999-06-15       Impact factor: 6.167

2.  Agonist-induced up-regulation of alpha4beta2 nicotinic acetylcholine receptors in M10 cells: pharmacological and spatial definition.

Authors:  P Whiteaker; C G Sharples; S Wonnacott
Journal:  Mol Pharmacol       Date:  1998-05       Impact factor: 4.436

3.  Differential inhibition by alpha-conotoxin-MII of the nicotinic stimulation of [3H]dopamine release from rat striatal synaptosomes and slices.

Authors:  S A Kaiser; L Soliakov; S C Harvey; C W Luetje; S Wonnacott
Journal:  J Neurochem       Date:  1998-03       Impact factor: 5.372

4.  Autoradiographic evidence for nicotine receptors on nigrostriatal and mesolimbic dopaminergic neurons.

Authors:  P B Clarke; A Pert
Journal:  Brain Res       Date:  1985-12-02       Impact factor: 3.252

5.  Beta 3: a new member of nicotinic acetylcholine receptor gene family is expressed in brain.

Authors:  E S Deneris; J Boulter; L W Swanson; J Patrick; S Heinemann
Journal:  J Biol Chem       Date:  1989-04-15       Impact factor: 5.157

6.  Pharmacological characterization of neuronal acetylcholine gated ion channel receptor-mediated hippocampal norepinephrine and striatal dopamine release from rat brain slices.

Authors:  A I Sacaan; J L Dunlop; G K Lloyd
Journal:  J Pharmacol Exp Ther       Date:  1995-07       Impact factor: 4.030

7.  Nicotinic modulation of [3H]dopamine release from striatal synaptosomes: pharmacological characterisation.

Authors:  C Rapier; G G Lunt; S Wonnacott
Journal:  J Neurochem       Date:  1990-03       Impact factor: 5.372

8.  Anatoxin-a-evoked [3H]dopamine release from rat striatal synaptosomes.

Authors:  L Soliakov; T Gallagher; S Wonnacott
Journal:  Neuropharmacology       Date:  1995-11       Impact factor: 5.250

9.  Characterization of Nicotinic Acetylcholine Receptors Expressed by Cells of the SH-SY5Y Human Neuroblastoma Clonal Line.

Authors:  R J Lukas; S A Norman; L Lucero
Journal:  Mol Cell Neurosci       Date:  1993-02       Impact factor: 4.314

10.  Blockade of nicotinic receptor-mediated release of dopamine from striatal synaptosomes by chlorisondamine and other nicotinic antagonists administered in vitro.

Authors:  H el-Bizri; P B Clarke
Journal:  Br J Pharmacol       Date:  1994-02       Impact factor: 8.739

View more
  38 in total

1.  Identification of the nicotinic receptor subtypes expressed on dopaminergic terminals in the rat striatum.

Authors:  Michele Zoli; Milena Moretti; Alessio Zanardi; J Michael McIntosh; Francesco Clementi; Cecilia Gotti
Journal:  J Neurosci       Date:  2002-10-15       Impact factor: 6.167

Review 2.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

3.  Phantasmidine: an epibatidine congener from the ecuadorian poison frog Epipedobates anthonyi.

Authors:  Richard W Fitch; Thomas F Spande; H Martin Garraffo; Herman J C Yeh; John W Daly
Journal:  J Nat Prod       Date:  2010-03-26       Impact factor: 4.050

4.  Specific α4β2 nicotinic acetylcholine receptor binding of [F-18]nifene in the rhesus monkey.

Authors:  A T Hillmer; D W Wooten; J M Moirano; M Slesarev; T E Barnhart; J W Engle; R J Nickles; D Murali; M L Schneider; J Mukherjee; B T Christian
Journal:  Synapse       Date:  2011-08-31       Impact factor: 2.562

5.  Involvement of protein kinase C in the presynaptic nicotinic modulation of [(3)H]-dopamine release from rat striatal synaptosomes..

Authors:  L Soliakov; S Wonnacott
Journal:  Br J Pharmacol       Date:  2001-02       Impact factor: 8.739

6.  In vivo neurochemical characterization of anatoxin-a evoked dopamine release from striatum.

Authors:  F Campos; R Durán; L Vidal; L R F Faro; M Alfonso
Journal:  J Neural Transm (Vienna)       Date:  2006-08-08       Impact factor: 3.575

7.  Chronic exposure to nicotine upregulates the human (alpha)4((beta)2 nicotinic acetylcholine receptor function.

Authors:  B Buisson; D Bertrand
Journal:  J Neurosci       Date:  2001-03-15       Impact factor: 6.167

8.  Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in alpha4 nicotinic receptor subunit knockout mice.

Authors:  R E Ryan; S A Ross; J Drago; R E Loiacono
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

9.  α4β2 nicotinic acetylcholine receptors in the early postnatal mouse superior cervical ganglion.

Authors:  Petra Scholze; Anna Ciuraszkiewicz; Florian Groessl; Avi Orr-Urtreger; J Michael McIntosh; Sigismund Huck
Journal:  Dev Neurobiol       Date:  2011-05       Impact factor: 3.964

Review 10.  The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum.

Authors:  Sharon R Grady; Outi Salminen; Duncan C Laverty; Paul Whiteaker; J Michael McIntosh; Allan C Collins; Michael J Marks
Journal:  Biochem Pharmacol       Date:  2007-07-27       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.